Radius Pharma sells off part of its royalties, milestones in breast cancer drug Orserdu
14 Aug 2023
License out/in
Radius Pharmaceuticals is pulling in an upfront payment of $130 million from DRI Healthcare as part of a royalty purchase agreement for its breast cancer drug elacestrant, the Boston-based biotech announced Monday.
Radius Pharmaceuticals, a subsidiary of Radius Health, could also receive another $10 million from DRI if “certain events” happen. Radius will keep more than $200 million in potential commercial milestones from the Menarini Group, which snagged global commercial and development rights to elacestrant for only $30 million in July 2020.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.